Antidepressant could offer dementia protection

2 December 2015

Escitalopram, a substance commonly used to treat depression, anxiety and panic attacks, seems to offer protection against two neurotoxic chemicals linked to dementia, according to researchers at the Loyola University Medical Center.

The study was based on comparing 30 severely depressed people with 27 healthy subjects. The depressed participants were treated with escitalopram for 12 weeks, and then followed up to see what effect it had on them.

Of the 20 who completed the study, 80 per cent reported at least partial relief of their depressive symptoms. This is significant because depression can cause an inflammatory response that encourages the production of certain neurotoxins that can damage brain tissue.

The participants treated with escitalopram were found to have significantly lower levels of 3-hydroxykynurenine and quinolinic acid once they had completed the course of medication.

Although the study is relatively small, its authors hope it could pave the way for future research into the potential anti-dementia effects of antidepressants.

Posted by Edward Bartel



Health News is provided by Axonn Media in collaboration with Spire Healthcare. Please note that all copy above is ©Axonn Media and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare.

Find a treatment, test or scan available at:

or

Find a consultant

Use one or more of the options below to search for a consultant and link through to view their Spire profile.

or

Let us help you

fill out this form and we will get back to you:

Please select a hospital

We can call you

Please enter your details below and we will call you back.

What is the aim of your enquiry?

Please select a hospital

If we are unable to reach you by phone, please include your email address so that we can get in touch...

Categories

Healthcare

© Spire Healthcare Group plc (2016)